^
    4d
    LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • letrozole
    22d
    Ablation Compare With Surgery for Early Breast Cancer (clinicaltrials.gov)
    P=N/A, N=264, Recruiting, Peking University People's Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + AR positive + ER positive
    23d
    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
    P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jan 2027 --> Jul 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive
    |
    methotrexate IV
    25d
    RADIOLA: Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (clinicaltrials.gov)
    P2, N=65, Completed, SOLTI Breast Cancer Research Group | Recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • HER-2 negative + AR positive + ER positive
    |
    Lynparza (olaparib)
    28d
    Study of 68Ga-R10602 (clinicaltrials.gov)
    P1, N=36, Recruiting, Radionetics Oncology | Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    29d
    Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment (clinicaltrials.gov)
    P3, N=258, Recruiting, Fujian Cancer Hospital
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    capecitabine • AiRuiKang (dalpiciclib)
    1m
    Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    carboplatin • albumin-bound paclitaxel • Zolinza (vorinostat)
    1m
    A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=28, Recruiting, Xijing Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • ER positive • BRCA1 mutation • HER-2 negative • HRD • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    docetaxel • cyclophosphamide • AiRuiYi (fluzoparib)
    2ms
    Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=4, Terminated, Jennifer Lee Caswell-Jin | Phase classification: P1b --> P1
    Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)
    2ms
    The Frequency of PD-L1 Marker Expression in ER Positive, PR Positive, HER2 Negative Invasive Breast Carcinomas, and Its Correlation with Clinicopathological Factors Affecting Prognosis. (PubMed, Adv Biomed Res)
    Tumor subtype, tumor size, and axillary lymph node status showed no significant difference between the two groups (P value > 0.05). According to the results of this study, there is no relationship between the PD-L1 expression and well-known clinicopathological prognostic factors in ER-positive, PR-positive, and HER2-negative invasive breast carcinomas.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • ER positive • HER-2 negative • PD-L1 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    2ms
    ESPRESSOBREAST: Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers (clinicaltrials.gov)
    P=N/A, N=1050, Recruiting, Institut Claudius Regaud | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 overexpression • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 positive + HER-2 overexpression
    2ms
    A Case of Invasive Ductal Carcinoma with Axillary Skip Metastasis Confined to the Interpectoral (Rotter's) Lymph Node. (PubMed, Surg Case Rep)
    This extraordinarily rare case of axillary skip metastasis limited to the interpectoral node emphasizes the potential for false-negative SN biopsies. Careful review of preoperative images, particularly MRI images, is crucial to avoid understaging. Awareness of interpectoral node involvement may help guide appropriate treatment strategies for selected patients.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive